These Stocks Are Moving the Most Today: ASML, Nvidia, Morgan Stanley, United Airlines, J.B. Hunt, DJT, Novocure, and More
ASML extends losses after cutting sales guidance, Nvidia stock edges higher, and third-quarter earnings at Morgan Stanley top ...
The American Journal of Managed Care1h
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...
FierceBiotech2h
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Targeted Oncology2h
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Morgan Stanley and Cisco Shine, S&P 500 Eyes Rebound in Today’s Trading
S&P 500 and Nasdaq 100 futures steady amid tech losses. Morgan Stanley beats Q3 estimates, up 3%, and Cisco climbs 2% on AI ...
STAT3h
A controversial approval for Novocure’s device
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
Yahoo Finance4h
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel ...
The Pharma Letter5h
FDA approves Novocure’s Optune Lua
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...
MarketWatch5h
Novocure shares surge on cancer treatment approval, and other movers
Novocure shares are surging 35% after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung cancer. Interactive Brokers ...
kalkinemedia7h
A 10.7% Surge Recorded for NovoCure (NVCR); Future Gains Speculated
Highlights:,Significant Stock Surge:,NovoCure's shares rose by 10.7% to $17.78, driven by substantial trading volume following FDA approval of its Optune Lua device for metastatic non-small cell lung ...